Stevanato (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.
How this was made
The 30-second read
Why it matters
Key trading takeaways are the reported quarterly financial metrics, the divestiture impact on one-time expenses and adjusted margins, and product/platform milestones including regulatory approval for a liraglutide therapy using the Alina variable dose pen and the introduction of Deora.
Market read
The transcript provides concrete Q2 financials and execution milestones that can drive near-term positioning around differentiated drug delivery demand and margin trajectory.
What to watch
The Balda Brewer sale created one-time expenses (EUR 12.2m) and start-up costs; traders may need to separate adjusted margin improvement from underlying run-rate and watch for depreciation and utility cost headwinds mentioned in the call.
Background
Stevanato’s Q2 2026 call focuses on growth in high-value solutions (biologics and GLP-1 related delivery), portfolio optimization via the Balda Brewer divestiture, and execution on capacity expansion in the U.S. (Fishers) and Italy (Latina).
Ticker impact
Stevanato reported Q2 2026 revenue of EUR 302m, high-value solutions up 16% to EUR 135.9m (45% of revenue), plus margin and segment updates.
Moderate positive bias for the stock on earnings-day positioning, with upside contingent on continued order momentum and progress toward 2027 commercial production.
The article includes concrete quarterly financials (revenue, gross margin, adjusted operating margin) and specific operational catalysts (Balda Brewer divestiture, Alina regulatory approval milestone, Fishers/Latina capacity timelines). However, it does not provide full-year guidance or detailed order/backlog numbers, limiting conviction on magnitude.
Market effects
Reinforces demand strength for biologics and GLP-1 related drug delivery platforms, supporting sentiment for specialized device and cartridge suppliers.
Highlights Germany manufacturing as a key supply node, which can matter for European pharma device supply-chain risk perception.
European regulatory approval for a liraglutide therapy using Stevanato’s Alina platform is a cross-border commercialization signal for integrated drug delivery systems.
Counterpoint
Despite high-value growth and margin improvement, the company flags longer sales cycles and near-term product commercialization timing risk (Deora takes time to reach commercial stage).
Key entities
- companyStevanato Group
Reported Q2 2026 results and provided updates on divestiture, high-value solutions growth, and drug delivery platform milestones.
- subsidiaryBalda C. Brewer
California-based contract manufacturing subsidiary divested in Q2 2026, generating EUR 12.2m one-time expenses.
- product_platformAlina variable dose pen platform
Proprietary pen platform referenced in a customer’s liraglutide therapy regulatory approval across several European countries.
- product_platformDeora multi-use fixed-dose pen injector
New pen injector system introduced to address adherence needs; commercialization expected later.